Chemotherapy - Dra. Alabastro Flashcards
Etiology of cancer
characterized by a shift in the control mechanisms that govern cell proliferation and differentiation
PHASE OF CELL CYCLE: nuclear membrane breaks down, mitotic spindle forms, chromosomes condense
Mitotic Phase - Prophase
PHASE OF CELL CYCLE: chromosomes condense at the center
Mitotic Phase - Metaphase
PHASE OF CELL CYCLE: chromosomes separate into chromatids
Mitotic Phase - Anaphase
PHASE OF CELL CYCLE: cells divide into parent and daughter cells
Mitotic Phase - Telophase
PHASE OF CELL CYCLE: Resting phase
G0 Phase
PHASE OF CELL CYCLE: RNA synthesis
G1 Phase
PHASE OF CELL CYCLE: DNA Replication
Synthesis Phase
PHASE OF CELL CYCLE: Preparation for mitosis
G2 Phase
Crucial component of cells’ machinery for organizing and dividing chromosomes
Forms spindles during mitosis
Microtubules
Basis for advanced treatment therapy for cancer
Proteins in control of cell growth
Class 1 proteins
growth factors
Class 2 proteins
Receptors for growth factors and hormones
Class 3 proteins
Intracellular signal transducers
Class 4 proteins
Nuclear transcription factors
Class 5 proteins
cell-cycle control proteins
Factors affecting tissue growth
- Cell cycle time
- Growth fraction
- Total # of cells in the population
- Increased cell death rate
Stages of tumor growth
Lag Phase: cells try to accustom themselves
Log Phase: cells repeatedly double in number
Plateau Phase: leveling off of cell doubling
Causes of cancer cells overproduction
- Failure of abnormal cells to undergo apoptosis
- Inappropriate stimulation of cell proliferation by genetic abnormalities
- Abnormalities of tumor suppressor gene (p53)
- Tumor angiogenesis
Factor of tissue growth that determines MAXIMUM GROWTH RATE of tumor
Cell Cycle Time
Factor of tissue growth that determines portion of cells sensitive to drug
Growth Fraction
Factor of tissue growth that gives an index of how advanced the cancer is.
Total # of cells in population
Indications for Chemotherapy
- Cure certain malignancies
- Palliate symptoms
- Treat asymptomatic patients
- Allow less mutilating surgery
Contraindications to Chemotherapy
- Inadequate facilities
- Survival unlikely even if tumor shrinkage is accomplished
- Unlikely to obtain benefits because of severe debilitation
- Asymptomatic patient with slow growing incurable tumors
Primary treatment for advanced cancer for which no alternative treatment exists
Primary Induction
Patients with localized cancer for which alternative therapies exit but less than completely effective
Neoadjuvant example: CT, RT
Reduces the incidence of both local and systemic recurrence and to improve the overall survival
Adjuvant
CLASSIFICATION OF CELL-CYCLE SPECIFIC CHEMOTHERAPEUTIC DRUGS
- Antimetabolites
- Antitumor antibiotic
- Vinca alkaloids
- Epipodophyllotoxins
- Taxanes
CLASSIFICATION OF CHEMOTHERAPEUTIC DRUGS
Cell Cycle Specific Drugs
Cell Cycle non-specific drugs
Phase Specific Drugs
CLASSIFICATION OF CELL-CYCLE NON-SPECIFIC CHEMOTHERAPEUTIC DRUGS
- Alkylating Agents
- Anthracyclines
- Antitumor antibiotics
- Camptothecins
- Platinum Analogs
GOALS OF CANCER THERAPY
- Damage the DNA of the affected cancer cells
- Inhibit the synthesis of new DNA strands to stop the cell from replicating
- Stop mitosis
Why are combinations effective?
Prevents resistant clones Less cytotoxicity Biochemical enhancement of effects To have sanctuary access Rescue
Neutrophil count and platelet count should be modified when?
Absolute neutrophil count <120,000/mL
General Adverse Effects of CT drugs
Nausea & vomiting
Mucositis; Stomatitis
Baldness
Myelosuppression
When to modify drug dose in terms of renal toxicity?
Drugs that cause renal toxicity not administered unless creatinine clearance >55 ml/min (MTX; Cisplatin; Streptozocin)
Which drugs should have their dose reduced in cases of hepatic impairment
Vinca alkaloids
Anthracyclines
ALKYLATING AGENTS (give most commonly used drug): Nitrogen mustard
cyclophosphamide
ALKYLATING AGENTS (give most commonly used drug): Ethylenemelamine derivatives
Thiotepa
Altretamine
ALKYLATING AGENTS (give most commonly used drug): Alkyl Sulfonate
Busulfan
ALKYLATING AGENTS (give most commonly used drug): Triazene
Dacarbazine
ALKYLATING AGENTS (give most commonly used drug): Platinum Analogs
Cisplatin
Oxaloplatin
Adverse effects of platinum analogs
Nephrotoxicity
Ototoxicity
Neurotoxicity
Mechanism of action of ALKYLATING AGENTS
Attachment of alkyl groups to DNA bases at N7 guanine forms fragmented DNA
Characteristics of alkylating agents
Cell cycle non-specific
Phase non-specific
What should not be given in the administration of alkylating agents and why?
Do not give GLUTATHIONE as it can inactivate an alkylating agent
Which among alkylating agents has a direct vesicant effect on the skin?
Nitrogen mustard
Which alkylating agents are irritants?
Cisplatin
Dacarbazine
Indication of Chlorambucil (nitrogen mustard)
Chronic Lymphocytic Leukemia
Indication of cyclophosphamide IV/PO (nitrogen mustard)
BREAST
LYMPHOCYTIC LEUKEMIA
AE of cyclophosphamide IV/PO (nitrogen mustard)
Severe N/V
Alopecia
Hemorragic cystitis
Indication of THIOTEPA (ETHYLENEMELAMINE DERIVATIVE)
Breast and ovarian CA
Indication of Busulfan (alkyl sulfonate)
(CML) Chronic Myelogenous Leukemia
AE of Busulfan (alkyl sulfonate)
Pulmonary fibrosis
Interstitial Pneumonitis
Indication of Dacarbazine (triazene)
Melanoma
Hodgkin’s
Soft tissue sarcoma
AE of Dacarbazine (triazene)
CNS depression
Platinum analog that causes ototoxicity
Cisplatin
Platinum analog that causes severe N/V
carboplatin
Platinum analog indicated for COLON CA
Oxaliplatin IV
Oxaliplatin is resistant to?
Cisplatin
Alkylating Agent that causes SEVERE N/V
Cyclophosphamide
Alkylating agent that causes alopecia
Cyclophosphamide
Alkylating agent that causes hemorrhagic cystitis
Cyclophosphamide
Alkylating agent that causes REVERSIBLE neuropathy
Oxaliplatin
Alkylating agent that causes IRREVERSIBLE ototoxicity
Cisplatin
Carboplatin
MOA of NITROSOUREAS
alkylation and carbamoylatio
Characteristic of nitrosoureas
Highly lipid soluble allowing them to cross BBB
Has delayed myelosuppressive effects (6 - 8 weeks)
Nitrosourea with minimal bone marrow toxicity
Streptozocin
Irritant nitrosourea
Carmustine (BCNU)
Newest nitrosourea that is sugar-containing and indicated for insulin secreting islet cell pancreatic CA
Streptozocin
Prototype of antifolate (antimetabolite)
Methotrexate IV/PO
MOA of antimetabolites
inhibits critical enzymes involved in nucleic acid (NA) synthesis or become incorporated into the NA and produces incorrect codes
Antimetabolite that does not have a non-linear dose response curve
5-FU
Antimetabolites with both IV/PO preparation
Methotrexate
Mercaptopurine
Antifolate Methotrexate indication
Acute Lymphoblastic Anemia
Antifolate Methotrexate AE
Megaloblastic anemia
5-Fluorouracil mainly indicated for?
Breast and colorectal CA
5-Fluorouracil AE
Megaloblastic anemia
DEOXYCYTIDINE ANALOG Cytarabine indication
Acute Myelogenous Leukemia (AML)
PURINE ANTAGONIST mercaptopurine indication
Childhood acute leukemia
AML
MOA of VINCA ALKALOIDS (NATURAL PRODUCTS)
Inhibits tubulin polymerization resulting to metaphase arrest and inhibition of mitosis
common toxicity of vinca alkaloids
Leukopenia
Areflexia (neurotoxic)
Prototype of vinca alkaloid which is indicated for Acute Lymphoblastic Leukemia
Vincristine
Natural product that stabilizes microtubule polymer
Taxane
Taxanes can only be given via?
IV
How many percent of taxanes are excreted in the urine?
10% only
Main toxicity of taxanes
bone marrow /myelosuppression
Peripheral sensory neuropathy
Paclitaxel mainly indicated for?
Breast and lung CA
Toxicity of Paclitaxel
Myalgia
arthralgia
EPIPODOPHYLLOTOXIN MOA
Inhibits topoisomerase II to promote DNA breakage and arrest in S and early G2 phase
Characteristic of EPIPODOPHYLLOTOXIN
Cell cycle specific
EPIPODOPHYLLOTOXIN given as IV only
Teniposide
Most common ADR of EPIPODOPHYLLOTOXIN
diarrhea
EPIPODOPHYLLOTOXIN indicated for small and non-small lung CA
Etoposide
EPIPODOPHYLLOTOXIN indicated ALL
Teniposide
Natural product Topoisomerase I inhibitor which cuts and re-ligates ssDNA to cause damage
CAMPTOTHECINS
How is IRINOTECAN (IV CAMPTOTHECIN) eliminated from the body?
Through bile and feces
CAMPTOTHECIN for lung and ovarian CA
Toptecan
CAMPTOTHECIN for colorectal CA
IRINOTECAN (IV)
ANTICANCER ANTIBIOTICS that cause Topoisomerase II-dependent DNA cleavage & intercalate with DNA double helix
Anthracycline and Dactinomycin
ANTICANCER ANTIBIOTIC that complexes with Mg++ to DNA & Blocks DNA/RNA synthesis
Plicamycin
ANTICANCER ANTIBIOTIC that causes cross links between complementary strands of DNA that impair replication
Mitomycin
ANTICANCER ANTIBIOTIC that causes strand scission by interacting with O2 and iron
Bleomycin
ANTICANCER ANTIBIOTIC that poorly crosses BBB
Bleomycin
Cardiotoxic ANTICANCER ANTIBIOTICS
anthracyclines (DOXORUBICIN & DAUNOROBUCIN)
ANTICANCER ANTIBIOTICS that cause pukmonary fibrosis
Bleomycin
ANTICANCER ANTIBIOTIC that is hepatotoxic
Plicamycin
ANDROGEN ANTAGONIST for prostatic CA
Flutamide
AE of FLUTAMIDE
Hot flashes
impotence
loss of libido
Androgen hormone drug that causes cholestatic jaundice
Fluoxymesterone
AE of estrogen antagonist TAMOXIFEN
Hot flashes
Osteoporosis
AE of steroids
Immunosuppression
AE of ANASTROZOLE (aromatase inhibitor)
Myelosuppression
Indication of ANASTROZOLE
Advanced ER/PR (+) non-tamoxifien responsive breast cacner
Antiangiogenesis drug for colon CA
Bevacizumab
Treatment for ADR of cisplatin or cytoprotective against cisplatin
AMIFOSTINE
Serotonin antagonist for mgt of N/V during CT
ONDANSETRON
Management for myelosuppression AE
Give hematopoietic growth factors
Drug combination for Cervical Cancer
Cisplatin or Carboplatin + 5FU
Drug combination for Colon CA
FOLFIRI: 5-FU + Leucovorin + IRInotecan/Topotecan
FOLFOX: 5-FU + Leucovorin + OXaliplatin
CapeOx:
Capecitabine + Oxaliplatin
CapeOx +/- bevacizumab
Drug combination for Acute Lymphocytic Leukemia (ALL) REMISSION
Vincristine + Prednisone
Drug combination for Acute Lymphocytic Leukemia (ALL) maintenance
6-mercaptopurine + Methotrexate + Cyclophosphamide
Drug combination for Acute Myeloid Leukemia (AML)
Cytarabine + Doxorubicin
Drug combination for Chronic Lymphocytic Leukemia (CLL)
Chlorambucil + Prednisone
Drug combination for Chronic Myeloid Leukemia (CML)
Busulfan
Drug combination for adjuvant therapy to prevent relapse of BREAST CA
Anastrozole or letrozole/tamoxifen
Drug combination for BREAST CA with METS
AC: doxorubicin (Adriamycin) + cyclophosphamide + Paclitaxel/Docetaxel
Drug combination for BREAST CA
CAF: cyclophosphamide + doxorubicin (Adriamycin) + 5-FU
AC: doxorubicin (Adriamycin) + cyclophosphamide
CMFP: cyclophosphamide + methotrexate + 5-FU + prednisone
Drug combination for LUNG CA
Etoposide + cisplatin/carboplatin
Topotecan + other agents
Most popular breakthrough in cancer therapy
Nanotechnology
MOA of non-classic alkylating agents
DNA alkylation; methylates DNA and inhibits DNA synthesis and function
MOA of Platinum Analogs
Forms intrastrands and interstrand DNA cross-links; binds to nuclear and cytoplasmic proteins
Common AE of Nitrosoureas
Nausea and vomiting
Common toxicity of anthracyclines
Vesicant
Aromatase inhibitors that cause myelosuppression
Anastrozole
Aminoglutethimide
Letrozole